Overview
LABT market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
No longer tradingThis symbol is retired in our registry: it no longer trades, so it has no live decision and cannot be traded here.
- Last Close
- $0.57
- Last Trading Day
- 2026-11-05
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
- O
- 0.393000
- H
- 0.940700
- L
- 0.393000
- C
- 0.572200
- Vol
- 2,187,353.00
Daily history from Apr 23, 2026
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- stale
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $0.39
- Previous Close
- $0.20
- Day High
- $0.94
- Day Low
- $0.39
- 52 Week High
- $9.06
- 52 Week Low
- $0.17
- 7 Day Return
- +142.66%
- 30 Day Return
- -33.34%
- 90 Day Return
- -74.11%
- 1 Year Return
- —
- Daily Notional Volume
- $1.3M Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.27 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.22 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.17 – $98.20 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $462.1K.